APRE Stock Overview
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Aprea Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.50 |
| 52 Week High | US$8.85 |
| 52 Week Low | US$2.78 |
| Beta | 0 |
| 1 Month Change | -8.93% |
| 3 Month Change | -8.33% |
| 1 Year Change | 40.85% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -59.38% |
Recent News & Updates
Shareholder Returns
| APRE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | 1.3% | 3.3% |
| 1Y | 40.8% | 3.0% | 25.0% |
Return vs Industry: APRE exceeded the US Biotechs industry which returned 3% over the past year.
Return vs Market: APRE exceeded the US Market which returned 25% over the past year.
Price Volatility
| APRE volatility | |
|---|---|
| APRE Average Weekly Movement | 12.6% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APRE's share price has been volatile over the past 3 months.
Volatility Over Time: APRE's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 7 | Oren Gilad | www.aprea.com |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors.
Aprea Therapeutics, Inc. Fundamentals Summary
| APRE fundamental statistics | |
|---|---|
| Market cap | US$27.88m |
| Earnings (TTM) | -US$14.29m |
| Revenue (TTM) | US$583.23k |
51.2x
P/S Ratio-2.1x
P/E RatioIs APRE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APRE income statement (TTM) | |
|---|---|
| Revenue | US$583.23k |
| Cost of Revenue | US$7.63m |
| Gross Profit | -US$7.04m |
| Other Expenses | US$7.24m |
| Earnings | -US$14.29m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.63 |
| Gross Margin | -1,207.80% |
| Net Profit Margin | -2,449.59% |
| Debt/Equity Ratio | 0% |
How did APRE perform over the long term?
See historical performance and comparison